Usted buscó: kidney transplant recipients (Inglés - Maltés)

kidney transplant
trapjant renali

organ transplant recipients
pazjenti li jirċievu trapjanti ta’ organi

zurampic should not be initiated in kidney transplant recipients.
zurampic ma għandux jinbeda f’riċevituri ta’ trapjant tal-kliewi.

prophylaxis of kidney transplant rejection
profilassi ta’ rifjut ta’ trapjant tal-kliewi

kidney disease or kidney transplant.
mard tal-kliewi jew trapjant tal-kliewi.

liver transplant recipients - study 0126
pazjenti li jirċievu trapjant tal-fwied - studju 0126

clinical trial in liver transplant recipients
provi kliniċi f’reċipjenti ta’ trapjant tal-fwied

are on dialysis or had a recent kidney transplant
qegħda fuq dijalisi jew kellek trapjant riċenti tal-kliewi

table 1: dose of belatacept for renal transplant recipients
tabella 1: doża ta’ belatacept għal pazjenti li jirċievu trapjant tal-kliewi

if you suffer from kidney problems or have a kidney transplant
jekk għandek problemi bil-kliewi jew kellek trapjant ta’ kilwa

nutropinaq is used until the child receives a kidney transplant.
nutropinaq jintuża sakemm it- tifel/ tifla jirċievu trapjant tal- kliewi.

irolimus: used to prevent your body from rejecting a kidney transplant
sirolimus: użat sabiex jimpedixxi lill-ġisem milli jirrifjuta trapjant tal-kliewi

study 1 and 2: phase 3 studies in renal transplant recipients
studju 1 u 2: studji ta’ fażi 3 f’pazjenti li rċivew trapjant tal-kliewi

if you have received a kidney transplant if you are on kidney dialysis.
jekk tkun irċevejt trapjant tal-kliewi jekk qiegħed fuq dijaliżi tal-kliewi.

the safety and efficacy of telbivudine in liver transplant recipients are unknown.
is-sigurtà u l-effikaċja f’pazjenti li jkunu rċevew trapjant tal-fwied mhumiex magħrufa.

if children have had a kidney transplant, growth hormone treatment will be stopped.
jekk it-tfal ikunu għamlu trapjant tal-kliewi, il-kura bl-ormon tat-tkabbir tiġi mwaqqfa.

12 pharmacokinetic and pharmacodynamic study in renal transplant recipients (41 patients).
tagħrif fuq is- sigurtà ta ’ pazjenti pedjatriċi nkiseb minn studju farmakokinetiku u farmakodinamiku open label wieħed fuq pazjenti li kellhom trapjant renali (41 pazjent).

in kidney transplant, the starting dose is 0.20 to 0.30 mg per kilogram body weight.
fil- każ ta 'trapjant tal- kliewi, id- doża tal- bidu hi 0. 20 sa 0. 30 mg għal kull kilogramma li jiżen il- pazjent.

- autoimmune hepatitis; or history of autoimmune disease; immunosuppressed transplant recipients.
- epatite awtoimmuni; jew passat mediku ta ’ mard awtoimmuni; pazjenti immunosoppressi li

transplant recipients who are epstein-barr virus (ebv) seronegative or serostatus unknown.
pazjenti li jingħataw trapjant li huma seronegattivi għall-virus ta’ epstein-barr (ebv) jew li s-serostatus tagħhom mhuwiex magħruf.